对抗凝血剂,抗血小板剂和两者组合的比较安全性:系统性审查和网络元分析
在PubMed上查看摘要
概括
此摘要是机器生成的。由于血管栓塞,心肌梗塞和中风的高风险,不建议对急性冠状动脉综合征 (ACS) 进行单剂抗血小板治疗 (SAPT). 将非维生素K抗剂 (NOAC) 与SAPT结合使用是一种平衡的方法,可以降低这些风险.
科学领域
- 心脏病学
- 药理学
- 临床试验
背景情况
- 抗血栓治疗对于治疗急性冠状动脉综合征至关重要.
- 结合治疗 (抗凝血剂+抗血小板剂) 显示出比单一治疗更好的疗效和安全性.
- 这项研究侧重于在ACS患者中比较各种抗血栓策略的安全性.
研究的目的
- 进行网络分析,对不同抗血栓治疗的安全性进行比较和排名.
- 评估出血的主要结果和二次结果,包括死亡率,心肌梗塞,中风和栓塞.
主要方法
- 使用随机效应模型进行了频率网络元分析.
- 数据来源于30项随机临床试验,涉及135471名ACS患者.
- 通过比较八种不同的抗血栓策略来评估安全性.
主要成果
- 单剂抗血小板治疗 (SAPT) 的出血风险最低 (SUCRA=0. 5%),而维生素K对抗剂 (VKA) +双剂抗血小板治疗 (DAPT) 的出血风险最高 (SUCRA=99. 8%).
- 与单独使用DAPT相比,非维生素K对手口服抗凝剂 (NOAC) + DAPT的出血风险增加 (OR=1. 94).
- 与SAPT相比,NOAC+SAPT显著降低了血栓塞和心肌梗塞. 与SAPT相比,VKA降低了中风的风险. 不同治疗方法的死亡率没有显著差异.
结论
- 由于血管栓塞,心肌梗塞和中风的风险增加,ACS不建议使用SAPT.
- NOAC和SAPT的组合显示出有利的特征,可能在出血和栓塞风险降低之间提供最佳平衡.
- 这项研究已登记在PROSPERO (CRD42024542826) 中.
相关概念视频
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

